Open AccessIodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-γ-Inducible α-Chemokine CXCL10 Serum Levels in Patients with Active Graves’ Disease or Toxic Nodular Goiter
Author(s) -
Alessandro Antonelli,
Mario Rotondi,
Poupak Fallahi,
M Grosso,
Giuseppe Boni,
Silvia Ferrari,
Paola Romagnani,
Mario Serio,
Giuliano Mariani,
Ele Ferrannini
Publication year - 2007
Publication title -
the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2006-1571
Subject(s) - cxcl10 , medicine , graves' disease , autoimmune thyroiditis , thyroid , thyroiditis , endocrinology , goiter , chemokine , autoimmune disease , immunology , immune system , gastroenterology , disease
The mechanism of activation of the immune system after iodine-131 (131I) treatment of hyperthyroidism is still not fully clarified. Serum levels of CXCL10, a prototype of the CXC family of chemokines, are increased in several endocrine autoimmune conditions, and this chemokine plays a role at least in the initial phases of thyroid autoimmune disease and in Graves' disease (GD). OBJECTIVE, DESIGN, AND PATIENTS: The aim of the present study was to measure the serum CXCL10 levels in 20 patients with GD and 10 patients with toxic nodular goiter (TNG) before and 6 months after 131I treatment, when patients had achieved euthyroidism. Forty healthy subjects and 40 patients with autoimmune thyroiditis served as control groups.